AntonioJaimeSanchezMDFACP

Gastroenterology • Iowa City, IA

Hepatology & Liver Transplantation

Director of Hepatology Clinical Professor, Internal Medicine, University of Iowa College of Medicine

Join to view full profile

Dr. Sanchez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sanchez's full profile

Already have an account?

Office
200 Hawkins Dr
Iowa City, IA 52242
Phone+1 319-356-4901

Fax+1 319-384-8559

Summary

Dr. Antonio Sanchez is a transplant hepatologist and Professor of Medicine with a clinical and reserach focus in hepatology and liver transplantation. He currently serves as the Director of Hepatology at the University of Iowa Hospitals and Clinics and also leads the Gastroenterology and Hepatology Clinical Research Center. His academic enterprise lies in transplant hepatology, clinical nutrition, and medical education. Dr. Sanchez has contributed to reputable publications and conducted significant clinical trials focusing on metabolic dysfunction-associated steatotic liver disease, alpha-1-antitrypsin deficiency-related liver disease and primary biliary cholangitis. He completed his internal medicine residency at the University of Illinois and his fellowship at the Mayo Clinic College of Medicine in Jacksonville. He was honored with the 2024 Milleman M3 Faculty of the Year award from the University of Iowa Carver College of Medicine.

Education & Training

Mayo Clinic College of Medicine and Science (Jacksonville)Fellowship, Transplant Hepatology, 2006
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2002 - 2005
Universidad de Guayaquil, School of Medicine.Class of 2000

Certifications & Licensure

IA State Medical License 2006 - 2026
FL State Medical License 2005 - 2025
IL State Medical License 2002 - 2007
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

2024 Milleman M3 Faculty of the Year University of Iowa Carver College of Medicine, 2024

Clinical Trials

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis Start of enrollment: 2013 Jun 01
Completed
Phase 2
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Start of enrollment: 2014 Sep 18
Completed
Phase 2
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 Start of enrollment: 2016 Jul 13
Completed
Phase 3
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24
Terminated
Phase 2
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Apr 05
Terminated
Phase 3
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Start of enrollment: 2017 Feb 13
Terminated
Phase 3
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Jan 30
Terminated
Phase 3
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Start of enrollment: 2017 Apr 28
Completed
Phase 3
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis Start of enrollment: 2017 Dec 27
Completed
Phase 2
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH Start of enrollment: 2020 Jan 27
Terminated
Phase 2
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) Start of enrollment: 2020 Nov 11
Terminated
Phase 2
A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Start of enrollment: 2021 Apr 27
Completed
Phase 2
Phase 2b Study of GSK4532990 in Adults With NASH Start of enrollment: 2023 Jan 02
Recruiting
Phase 2
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Start of enrollment: 2023 Jun 23
Recruiting
Phase 2
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) Start of enrollment: 2021 Aug 19
Recruiting
Phase 3
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis Start of enrollment: 2022 Apr 01
Active, not recruiting
Phase 2, Phase 3
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis Start of enrollment: 2022 Oct 06
Active, not recruiting
Phase 2
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease Start of enrollment: 2023 Aug 08
Enrolling by invitation
Phase 3
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2021 Aug 09
Active, not recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis Start of enrollment: 2021 Sep 22
Recruiting
Phase 2
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Start of enrollment: 2021 Aug 24
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

29 citations
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Elisabet Reyes-Irisarri, Antonio Sánchez, J.A. García-Merino, Guadalupe Mengod
Journal of Neuropathology and Experimental Neurology. 2007-10-01
3 citations
The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study.
Heidi S Ahmed, Nikitha Gangasani, Manju B Jayanna, Michelle T Long, Antonio Sanchez
Journal of Clinical and Experimental Hepatology. 2022-11-12
6 citations
Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease
Heidi S. Ahmed, Natalie Pedersen, Manju Bengaluru Jayanna, Patrick Ten Eyck, Antonio J. Sanchez
Journal of General Internal Medicine. 2020-03-10

Journal Articles

Hyperammonemic encephalopathy: time course of MRI diffusion changes
Capizzano AA, Sanchez A, Moritani T, Yager J., Neurology, 2/21/2012
Isoniazid-associated pancreatitis
Sanchez AJ, Boken D, Infections in Medicine 21(12):622-623 · December 2004

Abstracts/Posters